Context Analytics, Inc. differentiates through transparency. We provide our historical data, along with results related to back tested results and alpha derivation, to clients, academia, and interested firms.
Data Sources
Latest From Context Analytics
From Signal to Conviction: The Moderna Move, Measured in Real Time
Moderna (NASDAQ: MRNA) delivered one of the sharpest single-name reactions of the year on Wednesday, August 19th, after Moderna and Merck announced their Phase 3 INTerpath-001 trial had positive results. It is the first randomized trial to validate a personalized neoantigen cancer vaccine, a milestone with implications well beyond melanoma given the nine ongoing trials in Moderna's broader INTerpath oncology program.
